Abraxane (Nab-Paclitaxel)

What it is and what it treats

Abraxane is a chemotherapy medicine containing paclitaxel bound to albumin nanoparticles, a formulation designed to deliver the cytotoxic taxane without the Cremophor EL solvent used in conventional paclitaxel products. Paclitaxel works by stabilising microtubules within cancer cells, preventing normal cell division and leading to cell death.

Regulatory approvals cover metastatic breast cancer after failure of prior combination chemotherapy for metastatic disease, first-line treatment of locally advanced or metastatic non-small cell lung cancer (in combination with carboplatin) in patients who are not candidates for surgery or radiotherapy, and first-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine).

As with all taxane chemotherapy, use of Abraxane requires assessment of a patient's overall fitness for chemotherapy, baseline blood counts and liver function, and ongoing monitoring throughout treatment cycles by a qualified oncology team.

Presentations and dosage forms

• Powder for suspension for infusion, 100 mg paclitaxel (as albumin-bound particles) per single-use vial
• Reconstituted with 0.9% sodium chloride solution to form an injectable suspension prior to intravenous infusion
• Supplied without added solvents such as Cremophor EL, distinguishing it from conventional solvent-based paclitaxel products

How it is administered

Regulatory labelling describes tumour-specific dosing based on body surface area (BSA). For metastatic breast cancer, a commonly described regimen is 260 mg/m² administered intravenously over approximately 30 minutes every three weeks. For non-small cell lung cancer, dosing is described as 100 mg/m² on days 1, 8 and 15 of each 21-day cycle in combination with carboplatin. For pancreatic adenocarcinoma, dosing is described as 125 mg/m² on days 1, 8 and 15 of each 28-day cycle in combination with gemcitabine.

Because Abraxane does not contain the solvent responsible for the hypersensitivity reactions seen with conventional paclitaxel, routine premedication with corticosteroids and antihistamines is not required by the label, and the infusion time is shorter than with solvent-based paclitaxel. Nonetheless, patients are observed during infusion for signs of reaction.

The label describes dose modifications for haematological toxicity (such as severe neutropenia), peripheral neuropathy, and hepatic impairment. Treatment is generally continued until disease progression or unacceptable toxicity, with the number of cycles determined by the treating oncologist based on response and tolerability.

Storage and handling

• Store unopened vials at 20–25 °C (room temperature) in the original carton to protect from light
• Do not refrigerate or freeze unopened vials
• After reconstitution, the suspension should be used promptly; the SmPC describes a limited in-use storage window under refrigeration if immediate use is not possible
• Do not use vials showing particulate matter or discolouration after reconstitution
• Handle and dispose of cytotoxic waste in accordance with local institutional hazardous drug procedures

Side effects

The following effects are described in the approved FDA prescribing information and EU product labelling for nab-paclitaxel. Management is directed by the treating oncology team.

Commonly reported

Serious effects requiring medical attention

Patients should contact their treatment centre promptly for fever, signs of infection, severe numbness or pain in the hands or feet, unusual bruising or bleeding, or breathing difficulty. Suspected adverse reactions should be reported through national pharmacovigilance systems.

Nab-paclitaxel vs conventional solvent-based paclitaxel

Abraxane differs from conventional paclitaxel (marketed as Taxol and generics) principally in its formulation. Conventional paclitaxel is dissolved in Cremophor EL, a solvent associated with a meaningful incidence of hypersensitivity reactions, which is why it requires premedication with corticosteroids, antihistamines and H2-antagonists before each infusion. Abraxane instead binds paclitaxel to human albumin nanoparticles, avoiding Cremophor EL and its associated premedication requirement.

Clinical and pharmacokinetic studies cited in regulatory submissions describe higher intratumoural drug delivery with the albumin-bound formulation and a shorter infusion time (around 30 minutes for Abraxane versus approximately three hours for solvent-based paclitaxel). Reported rates of hypersensitivity are lower with Abraxane, while overlapping toxicities such as neutropenia, peripheral neuropathy, fatigue and alopecia occur with both formulations at broadly similar frequencies.

The two formulations are not interchangeable on a milligram-for-milligram basis; dosing schedules, cycle lengths and approved indications differ between the two products, and dose conversion should only be performed under oncologist supervision using the respective approved labelling for each formulation.

Availability and supply route

Abraxane's registration status differs by country: it is approved by the FDA in the United States and by the EMA in the European Union, alongside authorisations in many other jurisdictions, but the approved indications and locally available pack sizes can vary. Institutions should confirm current local labelling before ordering.

As a cytotoxic chemotherapy medicine, Abraxane is supplied and administered only against a valid prescription from a qualified oncologist, typically within a hospital or specialist infusion unit equipped to handle cytotoxic agents safely. In some countries, named-patient supply arrangements allow a specific patient's prescribed treatment to be sourced where the product is not locally registered, subject to national import and safety regulations.

Pricing for Abraxane is set nationally through each country's own reimbursement, tender or wholesale-pricing mechanisms and is not published on this site. Pharmacy Remedy is a licensed Turkish pharmaceutical wholesaler that supplies healthcare institutions and licensed pharmacies against valid documentation and does not sell prescription medicines directly to members of the public.

Frequently asked questions

Primary sources

• EMA — Abraxane product information
• FDA — Abraxane prescribing information

Further reading and regulatory routes

• How to verify a medicine is genuine
• Why medicines cost less in Türkiye
• WHO falsified medicine alerts
• Named patient supply
• UAE import guide
• For healthcare professionals
• All medicine monographs

Related medicines

• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Kyprolis (carfilzomib)